Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study

Gian Battista Fausto Bolis; G Scarfone; F Raspagliesi; G Mangili; S Danese; P Scollo; D Lo Russo; A Villa; Pd Aimone; Giovanni Scambia

doi:10.1016/j.ejca.2010.06.124

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study

Gian Battista Fausto Bolis, G Scarfone, F Raspagliesi, G Mangili, S Danese, P Scollo, D Lo Russo, A Villa, Pd Aimone, Giovanni Scambia

Research output: Contribution to journal › Article

36 Citations (Scopus)

Abstract

The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.

Original language	English
Pages (from-to)	2905-2912
Number of pages	8
Journal	European journal of cancer (Oxford, England : 1990)
Volume	46
DOIs	https://doi.org/10.1016/j.ejca.2010.06.124
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Ovarian Neoplasms
Paclitaxel
Topotecan
Treatment Outcome
Young Adult

Access to Document

10.1016/j.ejca.2010.06.124

Cite this

Bolis, G. B. F., Scarfone, G., Raspagliesi, F., Mangili, G., Danese, S., Scollo, P., Lo Russo, D., Villa, A., Aimone, P., & Scambia, G. (2010). Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. European journal of cancer (Oxford, England : 1990), 46, 2905-2912. https://doi.org/10.1016/j.ejca.2010.06.124

@article{712d68e325774037815ad2f705eb1f4b,

title = "Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study",

abstract = "The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.",

keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Ovarian Neoplasms, Paclitaxel, Topotecan, Treatment Outcome, Young Adult, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Ovarian Neoplasms, Paclitaxel, Topotecan, Treatment Outcome, Young Adult",

author = "Bolis, \{Gian Battista Fausto\} and G Scarfone and F Raspagliesi and G Mangili and S Danese and P Scollo and \{Lo Russo\}, D and A Villa and Pd Aimone and Giovanni Scambia",

year = "2010",

doi = "10.1016/j.ejca.2010.06.124",

language = "English",

volume = "46",

pages = "2905--2912",

journal = "European journal of cancer (Oxford, England : 1990)",

}

Bolis, GBF, Scarfone, G, Raspagliesi, F, Mangili, G, Danese, S, Scollo, P, Lo Russo, D, Villa, A, Aimone, P & Scambia, G 2010, 'Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study', European journal of cancer (Oxford, England : 1990), vol. 46, pp. 2905-2912. https://doi.org/10.1016/j.ejca.2010.06.124

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study. / Bolis, Gian Battista Fausto; Scarfone, G; Raspagliesi, F et al.
In: European journal of cancer (Oxford, England : 1990), Vol. 46, 2010, p. 2905-2912.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study

AU - Bolis, Gian Battista Fausto

AU - Scarfone, G

AU - Raspagliesi, F

AU - Mangili, G

AU - Danese, S

AU - Scollo, P

AU - Lo Russo, D

AU - Villa, A

AU - Aimone, Pd

AU - Scambia, Giovanni

PY - 2010

Y1 - 2010

N2 - The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.

AB - The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Topotecan

KW - Treatment Outcome

KW - Young Adult

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Paclitaxel

KW - Topotecan

KW - Treatment Outcome

KW - Young Adult

UR - http://hdl.handle.net/10807/32508

U2 - 10.1016/j.ejca.2010.06.124

DO - 10.1016/j.ejca.2010.06.124

M3 - Article

VL - 46

SP - 2905

EP - 2912

JO - European journal of cancer (Oxford, England : 1990)

JF - European journal of cancer (Oxford, England : 1990)

ER -

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this